Is GLSI or IMA more profitable?

ImageneBio's return on equity of -38.99% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Greenwich LifeSciences N/A -793.81% -295.32% ImageneBio N/A -38.99% -34.84%

Does the media refer more to IMA or EBS?

In the previous week, ImageneBio had 2 more articles in the media than Emergent Biosolutions. MarketBeat recorded 8 mentions for ImageneBio and 6 mentions for Emergent Biosolutions. ImageneBio's average media sentiment score of 0.80 beat Emergent Biosolutions' score of 0.11 indicating that ImageneBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImageneBio 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Emergent Biosolutions 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is ORGO or IMA more profitable?

ImageneBio has a net margin of 0.00% compared to Organogenesis' net margin of -19.94%. Organogenesis' return on equity of -23.89% beat ImageneBio's return on equity. Company Net Margins Return on Equity Return on Assets Organogenesis -19.94% -23.89% -11.13% ImageneBio N/A -38.99% -34.84%

Does the media refer more to IMA or AKBA?

In the previous week, ImageneBio had 6 more articles in the media than Akebia Therapeutics. MarketBeat recorded 8 mentions for ImageneBio and 2 mentions for Akebia Therapeutics. ImageneBio's average media sentiment score of 0.80 beat Akebia Therapeutics' score of 0.67 indicating that ImageneBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImageneBio 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akebia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMA or GALT more profitable?

Galectin Therapeutics' return on equity of 0.00% beat ImageneBio's return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.99% -34.84% Galectin Therapeutics N/A N/A -176.83%

Does the media prefer IMA or GALT?

In the previous week, ImageneBio had 2 more articles in the media than Galectin Therapeutics. MarketBeat recorded 8 mentions for ImageneBio and 6 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 1.05 beat ImageneBio's score of 0.80 indicating that Galectin Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImageneBio 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Galectin Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ImageneBio (IMA) Competitors

$5.51 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

IMA vs. GLSI, EBS, ORGO, AKBA, and GALT

Should you buy ImageneBio stock or one of its competitors? ImageneBio's main competitors and comparable companies include Greenwich LifeSciences (GLSI), Emergent Biosolutions (EBS), Organogenesis (ORGO), Akebia Therapeutics (AKBA), and Galectin Therapeutics (GALT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ImageneBio compare to Greenwich LifeSciences?

Greenwich LifeSciences (NASDAQ:GLSI) and ImageneBio (NASDAQ:IMA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

Greenwich LifeSciences has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market. Comparatively, ImageneBio has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

ImageneBio's return on equity of -38.99% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-793.81%	-295.32%
ImageneBio	N/A	-38.99%	-34.84%

Greenwich LifeSciences has higher earnings, but lower revenue than ImageneBio. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.54	N/A
ImageneBio	$800K	78.17	-$45.35M	-$4.58	N/A

Greenwich LifeSciences currently has a consensus price target of $69.00, suggesting a potential upside of 313.92%. ImageneBio has a consensus price target of $29.00, suggesting a potential upside of 426.32%. Given ImageneBio's stronger consensus rating and higher probable upside, analysts clearly believe ImageneBio is more favorable than Greenwich LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20

4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 51.5% of Greenwich LifeSciences shares are owned by insiders. Comparatively, 2.2% of ImageneBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, ImageneBio had 8 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 8 mentions for ImageneBio and 0 mentions for Greenwich LifeSciences. ImageneBio's average media sentiment score of 0.80 beat Greenwich LifeSciences' score of 0.00 indicating that ImageneBio is being referred to more favorably in the news media.

Company	Overall Sentiment
Greenwich LifeSciences	Neutral
ImageneBio	Positive

Summary

ImageneBio beats Greenwich LifeSciences on 10 of the 14 factors compared between the two stocks.

How does ImageneBio compare to Emergent Biosolutions?

ImageneBio (NASDAQ:IMA) and Emergent Biosolutions (NYSE:EBS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

ImageneBio has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Emergent Biosolutions has a beta of 2.35, indicating that its share price is 135% more volatile than the broader market.

ImageneBio currently has a consensus target price of $29.00, indicating a potential upside of 426.32%. Emergent Biosolutions has a consensus target price of $10.00, indicating a potential upside of 97.24%. Given ImageneBio's stronger consensus rating and higher possible upside, research analysts plainly believe ImageneBio is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

ImageneBio has a net margin of 0.00% compared to Emergent Biosolutions' net margin of -22.95%. Emergent Biosolutions' return on equity of 16.35% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.99%	-34.84%
Emergent Biosolutions	-22.95%	16.35%	6.17%

75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are owned by institutional investors. 2.2% of ImageneBio shares are owned by insiders. Comparatively, 6.0% of Emergent Biosolutions shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, ImageneBio had 2 more articles in the media than Emergent Biosolutions. MarketBeat recorded 8 mentions for ImageneBio and 6 mentions for Emergent Biosolutions. ImageneBio's average media sentiment score of 0.80 beat Emergent Biosolutions' score of 0.11 indicating that ImageneBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImageneBio	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Emergent Biosolutions	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Emergent Biosolutions has higher revenue and earnings than ImageneBio. Emergent Biosolutions is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	78.17	-$45.35M	-$4.58	N/A
Emergent Biosolutions	$742.90M	0.35	$52.60M	-$3.55	N/A

Summary

Emergent Biosolutions beats ImageneBio on 9 of the 17 factors compared between the two stocks.

How does ImageneBio compare to Organogenesis?

Organogenesis (NASDAQ:ORGO) and ImageneBio (NASDAQ:IMA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

Organogenesis has higher revenue and earnings than ImageneBio. Organogenesis is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$454.61M	0.51	$37.03M	-$0.86	N/A
ImageneBio	$800K	78.17	-$45.35M	-$4.58	N/A

ImageneBio has a net margin of 0.00% compared to Organogenesis' net margin of -19.94%. Organogenesis' return on equity of -23.89% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-19.94%	-23.89%	-11.13%
ImageneBio	N/A	-38.99%	-34.84%

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 75.0% of ImageneBio shares are held by institutional investors. 18.8% of Organogenesis shares are held by company insiders. Comparatively, 2.2% of ImageneBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, ImageneBio had 8 more articles in the media than Organogenesis. MarketBeat recorded 8 mentions for ImageneBio and 0 mentions for Organogenesis. ImageneBio's average media sentiment score of 0.80 beat Organogenesis' score of 0.00 indicating that ImageneBio is being referred to more favorably in the news media.

Company	Overall Sentiment
Organogenesis	Neutral
ImageneBio	Positive

Organogenesis has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market. Comparatively, ImageneBio has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

Organogenesis currently has a consensus price target of $4.33, indicating a potential upside of 140.74%. ImageneBio has a consensus price target of $29.00, indicating a potential upside of 426.32%. Given ImageneBio's stronger consensus rating and higher possible upside, analysts plainly believe ImageneBio is more favorable than Organogenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20

Summary

ImageneBio beats Organogenesis on 10 of the 17 factors compared between the two stocks.

How does ImageneBio compare to Akebia Therapeutics?

ImageneBio (NASDAQ:IMA) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

In the previous week, ImageneBio had 6 more articles in the media than Akebia Therapeutics. MarketBeat recorded 8 mentions for ImageneBio and 2 mentions for Akebia Therapeutics. ImageneBio's average media sentiment score of 0.80 beat Akebia Therapeutics' score of 0.67 indicating that ImageneBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImageneBio	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akebia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImageneBio has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market.

Akebia Therapeutics has higher revenue and earnings than ImageneBio. Akebia Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	78.17	-$45.35M	-$4.58	N/A
Akebia Therapeutics	$236.20M	1.06	-$5.34M	-$0.11	N/A

75.0% of ImageneBio shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 2.2% of ImageneBio shares are held by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ImageneBio currently has a consensus target price of $29.00, indicating a potential upside of 426.32%. Akebia Therapeutics has a consensus target price of $3.75, indicating a potential upside of 313.63%. Given ImageneBio's higher probable upside, research analysts clearly believe ImageneBio is more favorable than Akebia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

ImageneBio has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. ImageneBio's return on equity of -38.99% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.99%	-34.84%
Akebia Therapeutics	-13.54%	-88.88%	-7.74%

Summary

ImageneBio beats Akebia Therapeutics on 10 of the 17 factors compared between the two stocks.

How does ImageneBio compare to Galectin Therapeutics?

ImageneBio (NASDAQ:IMA) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Galectin Therapeutics' return on equity of 0.00% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.99%	-34.84%
Galectin Therapeutics	N/A	N/A	-176.83%

ImageneBio has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market.

In the previous week, ImageneBio had 2 more articles in the media than Galectin Therapeutics. MarketBeat recorded 8 mentions for ImageneBio and 6 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 1.05 beat ImageneBio's score of 0.80 indicating that Galectin Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImageneBio	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Galectin Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

75.0% of ImageneBio shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 2.2% of ImageneBio shares are held by insiders. Comparatively, 52.6% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ImageneBio presently has a consensus target price of $29.00, indicating a potential upside of 426.32%. Galectin Therapeutics has a consensus target price of $11.00, indicating a potential upside of 198.91%. Given ImageneBio's stronger consensus rating and higher probable upside, equities research analysts clearly believe ImageneBio is more favorable than Galectin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Galectin Therapeutics has lower revenue, but higher earnings than ImageneBio. Galectin Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	78.17	-$45.35M	-$4.58	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A

Summary

ImageneBio beats Galectin Therapeutics on 9 of the 14 factors compared between the two stocks.

Get ImageneBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMA vs. The Competition

Export

Metric	ImageneBio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$62.54M	$4.00B	$7.32B	$12.82B
Dividend Yield	N/A	3.64%	2.54%	10.78%
P/E Ratio	-1.20	11.68	272.91	24.33
Price / Sales	78.17	1,378.82	639.67	97.25
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	0.46	17.57	11.33	6.42
Net Income	-$45.35M	-$22.72M	$3.47B	$348.89M
7 Day Performance	-1.25%	2.74%	2.18%	0.51%
1 Month Performance	-1.43%	9.64%	7.61%	4.84%
1 Year Performance	-61.28%	54.98%	25.16%	17.04%

ImageneBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMA ImageneBio	2.9978 of 5 stars	$5.51 flat	$29.00 +426.3%	-61.3%	$62.54M	$800K	N/A	70	Analyst Forecast Gap Up High Trading Volume
GLSI Greenwich LifeSciences	2.189 of 5 stars	$17.34 +0.5%	$57.00 +228.7%	+36.9%	$254.55M	N/A	N/A	3
EBS Emergent Biosolutions	2.9835 of 5 stars	$4.90 +5.2%	$10.00 +103.9%	-45.1%	$251.44M	$742.30M	N/A	2,420	Analyst Forecast
ORGO Organogenesis	1.3719 of 5 stars	$1.91 +6.7%	$4.33 +126.9%	-63.2%	$245.78M	$564.17M	N/A	950	Analyst Downgrade
AKBA Akebia Therapeutics	2.2956 of 5 stars	$0.89 +3.9%	$3.75 +323.5%	-71.6%	$245.35M	$236.20M	N/A	430	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMA) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImageneBio (IMA) Competitors

IMA vs. GLSI, EBS, ORGO, AKBA, and GALT

How does ImageneBio compare to Greenwich LifeSciences?

Summary

How does ImageneBio compare to Emergent Biosolutions?

Summary

How does ImageneBio compare to Organogenesis?

Summary

How does ImageneBio compare to Akebia Therapeutics?

Summary

How does ImageneBio compare to Galectin Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMA vs. The Competition

ImageneBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImageneBio (IMA) Competitors

IMA vs. GLSI, EBS, ORGO, AKBA, and GALT

How does ImageneBio compare to Greenwich LifeSciences?

Which has more volatility and risk, GLSI or IMA?

Is GLSI or IMA more profitable?

Which has better earnings & valuation, GLSI or IMA?

Do analysts recommend GLSI or IMA?

Do insiders & institutionals hold more shares of GLSI or IMA?

Does the media prefer GLSI or IMA?

Summary

How does ImageneBio compare to Emergent Biosolutions?

Which has more risk & volatility, IMA or EBS?

Do analysts prefer IMA or EBS?

Is IMA or EBS more profitable?

Do insiders and institutionals have more ownership in IMA or EBS?

Does the media refer more to IMA or EBS?

Which has stronger earnings and valuation, IMA or EBS?

Summary

How does ImageneBio compare to Organogenesis?

Which has better valuation & earnings, ORGO or IMA?

Is ORGO or IMA more profitable?

Do institutionals & insiders believe in ORGO or IMA?

Does the media favor ORGO or IMA?

Which has more risk & volatility, ORGO or IMA?

Do analysts recommend ORGO or IMA?

Summary

How does ImageneBio compare to Akebia Therapeutics?

Does the media refer more to IMA or AKBA?

Which has more volatility & risk, IMA or AKBA?

Which has higher earnings and valuation, IMA or AKBA?

Do institutionals and insiders believe in IMA or AKBA?

Do analysts recommend IMA or AKBA?

Is IMA or AKBA more profitable?

Summary

How does ImageneBio compare to Galectin Therapeutics?

Is IMA or GALT more profitable?

Which has more volatility & risk, IMA or GALT?

Does the media prefer IMA or GALT?

Do institutionals & insiders hold more shares of IMA or GALT?

Do analysts rate IMA or GALT?

Which has stronger earnings & valuation, IMA or GALT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMA vs. The Competition

ImageneBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools